Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MYRIAD GENETICS INC

Get SEC filing alerts via email and in your feed for MYRIAD GENETICS INC

MYGN

MYRIAD GENETICS INC

About MYRIAD GENETICS INC

Myriad Genetics, Inc. is a molecular diagnostic company specializing in precision medicine. It develops and offers genetic and genomic tests across oncology, women’s health, and pharmacogenomics to assess disease risk, guide treatment, and improve patient outcomes. Serving healthcare providers and patients, the company leverages innovative technologies, clinical evidence, and regulatory expertise to deliver actionable insights and support personalized healthcare.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MYRIAD GENETICS INC

1
1
MYRIAD GENETICS INC Myriad Genetics Reports $200.4 Million Revenue with Increased Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
MYRIAD GENETICS INC Myriad Genetics Reports $824.5M Revenue and $365.9M Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
MYRIAD GENETICS INC Myriad Genetics Reports Q3 2025 Revenue Decline and Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MYRIAD GENETICS INC Myriad Genetics Reports $330.5 Million Net Loss and $213.1 Million Revenue for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MYRIAD GENETICS INC Myriad Genetics Reports $195.9 Million Revenue, Net Loss Improvement in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MYRIAD GENETICS INC Myriad Genetics Reports $837.6M Revenue and $127.3M Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
MYRIAD GENETICS INC Myriad Genetics Reports 11% Revenue Growth, Improved Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments